WallStSmart

Merck & Company Inc (MRK)vsSilence Therapeutics PLC (SLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 7838756% more annual revenue ($65.77B vs $839,000). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

SLN

Avoid

27

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -6.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-62.3%)

Margin of Safety

-62.3%

Fair Value

$81.23

Current Price

$129.79

$48.56 premium

UndervaluedFair: $81.23Overvalued

Intrinsic value data unavailable for SLN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$307.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

SLN2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
197.2%10/10

Revenue surging 197.2% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SLN4 concerns · Avg: 3.5/10
Price/BookValuation
11.0x4/10

Trading at 11.0x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$495.96M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : SLN

The strongest argument for SLN centers on Revenue Growth, Debt/Equity. Revenue growth of 197.2% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : SLN

The primary concerns for SLN are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

MRK profiles as a value stock while SLN is a hypergrowth play — different risk/reward profiles.

SLN carries more volatility with a beta of 1.38 — expect wider price swings.

SLN is growing revenue faster at 197.2% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Silence Therapeutics PLC

HEALTHCARE · BIOTECHNOLOGY · USA

Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology, cardiovascular, and other rare and metabolic indications. The company is headquartered in London, the United Kingdom.

Want to dig deeper into these stocks?